ATE469650T1 - Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz - Google Patents

Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz

Info

Publication number
ATE469650T1
ATE469650T1 AT04028474T AT04028474T ATE469650T1 AT E469650 T1 ATE469650 T1 AT E469650T1 AT 04028474 T AT04028474 T AT 04028474T AT 04028474 T AT04028474 T AT 04028474T AT E469650 T1 ATE469650 T1 AT E469650T1
Authority
AT
Austria
Prior art keywords
megestrol acetate
improve
heart
treat
heart failure
Prior art date
Application number
AT04028474T
Other languages
English (en)
Inventor
Stefan Anker
Original Assignee
Par Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Par Pharmaceuticals Inc filed Critical Par Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE469650T1 publication Critical patent/ATE469650T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04028474T 2004-12-01 2004-12-01 Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz ATE469650T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04028474A EP1669074B1 (de) 2004-12-01 2004-12-01 Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz

Publications (1)

Publication Number Publication Date
ATE469650T1 true ATE469650T1 (de) 2010-06-15

Family

ID=34927608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04028474T ATE469650T1 (de) 2004-12-01 2004-12-01 Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz

Country Status (9)

Country Link
US (3) US8383612B2 (de)
EP (2) EP1669074B1 (de)
AT (1) ATE469650T1 (de)
DE (1) DE602004027515D1 (de)
DK (1) DK1669074T3 (de)
ES (2) ES2346755T3 (de)
PL (1) PL1863492T3 (de)
SI (1) SI1669074T1 (de)
WO (1) WO2006058748A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101277097B1 (ko) 2004-12-23 2013-06-20 체에스엘 베링 게엠베하 혈전 형성 및/또는 안정화의 예방
WO2009071405A1 (en) * 2007-12-04 2009-06-11 Charité - Universitätsmedizin Berlin Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients
US10334873B2 (en) * 2016-06-16 2019-07-02 Altria Client Services Llc Breakable capsules and methods of forming thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370321A (en) * 1976-09-01 1983-01-25 Mead Johnson And Company Progestational adjuvant therapy
US5144017A (en) * 1988-07-13 1992-09-01 University Of Manitoba Compounds that bind to digitalis receptor
SE9600046D0 (sv) * 1996-01-05 1996-01-05 Astra Ab New pharmaceutical formulation
AU2003230885A1 (en) * 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
EP1558265B1 (de) * 2002-11-05 2010-01-06 Bayer Schering Pharma Aktiengesellschaft Verwendung von drospirenon zur behandlung von hypertension

Also Published As

Publication number Publication date
DE602004027515D1 (de) 2010-07-15
PL1863492T3 (pl) 2013-10-31
EP1863492B1 (de) 2013-05-08
SI1669074T1 (sl) 2010-10-29
US20130143848A1 (en) 2013-06-06
US20160101117A1 (en) 2016-04-14
ES2423944T3 (es) 2013-09-25
EP1669074B1 (de) 2010-06-02
EP1863492A1 (de) 2007-12-12
DK1669074T3 (da) 2010-09-27
WO2006058748A1 (en) 2006-06-08
ES2346755T3 (es) 2010-10-20
EP1669074A1 (de) 2006-06-14
US8383612B2 (en) 2013-02-26
US20080139521A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
ATE521608T1 (de) Glucokinaseaktivatoren
NO20070257L (no) Forbindelser, blandinger og metoder
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
ATE539748T1 (de) Glucokinaseaktivatoren
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
MX2007007781A (es) Composiciones cardiovasculares.
EA201000515A1 (ru) Активаторы глюкокиназы
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
ATE534747T1 (de) 1l1rl-1 als marker für kardiovaskuläre erkrankungen
ATE400297T1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
EA200900392A1 (ru) Комбинированное лечение сахарного диабета
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
ATE501718T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
EP1807509A4 (de) Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit
DE602005011468D1 (de) Gemeinsame gabe von tigecyclin und digoxin
ATE449600T1 (de) Verwendung von glycerin zur verbesserung der herzfunktion
ATE469650T1 (de) Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz
DE602004010691D1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE602005013542D1 (de) Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties